A pharmacological study of Cyperus rotundus.

N. Singh,V. Kulshrestha,M. B. Gupta,K. Bhargava

The Indian Journal of Medical Research

Abstract:

What problem does this paper attempt to address?

Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review

Alexis M. Sanwick,Ivis F. Chaple

DOI: https://doi.org/10.3389/fonc.2024.1445191

IF: 4.7

2024-08-22

Frontiers in Oncology

Abstract:Head and neck squamous cell carcinoma (HNSCC) is a type of head and neck cancer that is aggressive, difficult to treat, and often associated with poor prognosis. HNSCC is the sixth most common cancer worldwide, highlighting the need to develop novel treatments for this disease. The current standard of care for HNSCC usually involves a combination of surgical resection, radiation therapy, and chemotherapy. Chemotherapy is notorious for its detrimental side effects including nausea, fatigue, hair loss, and more. Radiation therapy can be a challenge due to the anatomy of the head and neck area and presence of normal tissues. In addition to the drawbacks of chemotherapy and radiation therapy, high morbidity and mortality rates for HNSCC highlight the urgent need for alternative treatment options. Immunotherapy has recently emerged as a possible treatment option for cancers including HNSCC, in which monoclonal antibodies are used to help the immune system fight disease. Combining monoclonal antibodies approved by the US Food and Drug Administration, such as cetuximab and pembrolizumab, with radiotherapy or platinum-based chemotherapy for patients with locally advanced, recurrent, or metastatic HNSCC is an accepted first-line therapy. Targeted radionuclide therapy can potentially be used in conjunction with the first-line therapy, or as an additional treatment option, to improve patient outcomes and quality of life. Epidermal growth factor receptor is a known molecular target for HNSCC; however, other targets such as human epidermal growth factor receptor 2, human epidermal growth factor receptor 3, programmed cell death protein 1, and programmed death-ligand 1 are emerging molecular targets for the diagnosis and treatment of HNSCC. To develop successful radiopharmaceuticals, it is imperative to first understand the molecular biology of the disease of interest. For cancer, this understanding often means detection and characterization of molecular targets, such as cell surface receptors, that can be used as sensitive targeting agents. The goal of this review article is to explore molecular targets for HNSCC and dissect previously conducted research in nuclear medicine and provide a possible path forward for the development of novel radiopharmaceuticals used in targeted radionuclide therapy for HNSCC, which has been underexplored to date.

oncology
Advances in Nonsurgical Treatment of Head and Neck Squamous Cell Carcinoma

Zang Shoumei,Yan Danfang,Yan Senxiang

DOI: https://doi.org/10.3760/cma.j.issn.1673-422x.2019.12.007

2019-01-01

Abstract:Locally advanced head and neck squamous cell carcinoma requires a multidisciplinary approach, including surgery followed by radiotherapy, with or without chemotherapy, or definitive concurrent chemoradiotherapy. The application of induction chemotherapy remains controversial. Cetuximab has achieved satisfactory results in the treatment of head and neck squamous cell carcinoma. Immunocheckpoint inhibitors against the receptor programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have demonstrated clinical efficacy in head and neck squamous carcinoma. However, only a small subset of patients can benefit from anti-PD-1 and anti-PD-L1 monotherapy. To improve the effectiveness of immunotherapy, combined of immunotherapy and other treatments has become an alternative strategy. Key words: Head and neck neoplasms; Radiotherapy; Cetuximab; Immunotherapy; Chemotherapy
Nanoparticle-Based Targeted Therapeutics In Head-And-Neck Cancer

Ting-Ting Wu,Shui-Hong Zhou

DOI: https://doi.org/10.7150/ijms.10083

2015-01-01

International Journal of Medical Sciences

Abstract:Head-and-neck cancer is a major form of the disease worldwide. Treatment consists of surgery, radiation therapy and chemotherapy, but these have not resulted in improved survival rates over the past few decades. Versatile nanoparticles, with selective tumor targeting, are considered to have the potential to improve these poor outcomes. Application of nanoparticle-based targeted therapeutics has extended into many areas, including gene silencing, chemotherapeutic drug delivery, radiosensitization, photothermal therapy, and has shown much promise. In this review, we discuss recent advances in the field of nanoparticle-mediated targeted therapeutics for head-and-neck cancer, with an emphasis on the description of targeting points, including future perspectives.
Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists

Daniel Tao Xing,Richard Khor,Hui Gan,Morikatsu Wada,Tai Ermongkonchai,Sweet Ping Ng

DOI: https://doi.org/10.3390/cancers13225716

2021-11-15

Cancers

Abstract:Radiotherapy plays an important role of managing head and neck squamous cell carcinoma (HNSCC). Concurrent radiotherapy with radiosensitizing cisplastin chemotherapy is the standard of care (SOC) for non-operable locally advanced HNSCC. Cetuximab, a monoclonal antibody of epidermal growth factor receptor, was the most extensively studied targeted therapy as a chemo-sparing agent that was used concurrently with radiotherapy. Immunotherapy is used in the treatment of metastatic HNSCC. There is evidence to support the synergistic effect when combining radiotherapy with immunotherapy to potentiate anti-tumor immune response. There has been increasing interest to incorporate immune checkpoint inhibitor (ICI) with radiotherapy in the curative setting for HNSCC. In this review, we discuss the latest evidence that supports concurrent radiotherapy with cisplatin which remains the SOC for locally advanced HNSCC (LA-HNSCC). Cetuximab is suitable for patients who are not fit for cisplatin. We then summarize the clinical trials that incorporate ICI with radiotherapy for LA-HNSCC in concurrent, neoadjuvant, and adjuvant settings. We also discuss the potential of combining immunotherapy with radiotherapy as a treatment de-escalating strategy in HPV-associated oropharyngeal carcinoma. Finally, the pre-clinical and clinical evidence of the abscopal effect when combining stereotactic body radiotherapy with ICIs is presented.

oncology
New Advances in the Therapeutic Strategy of Head and Neck Squamous Cell Carcinoma: A Review of Latest Therapies and Cutting-Edge Research

Yuting Wang,Jing Han,Yongxue Zhu,Naisi Huang,Ning Qu

DOI: https://doi.org/10.1016/j.bbcan.2024.189230

IF: 11.414

2024-01-01

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Abstract:Head and neck squamous cell carcinoma (HNSCC) is a common and aggressive malignancy with a poor prognosis, particularly when diagnosed at advanced stages. Despite progress in surgical, chemotherapeutic, and radiotherapeutic interventions, the five-year survival rate remains low due to high rates of recurrence and therapeutic resistance. This review explores recent advances in therapeutic strategies for HNSCC, focusing on targeted therapies, immunotherapy, and innovative drug delivery systems.Targeted therapies, such as EGFR inhibitors and PI3K/AKT/mTOR pathway inhibitors, offer promising options for overcoming HNSCC, though resistance challenges persist. Emerging treatments, including dual-target inhibitors and personalized therapeutic approaches, show potential in addressing these limitations. Immunotherapy, particularly PD-1/PD-L1 blockade, has achieved positive outcomes in a subset of patients, though overall response rates remain modest. Strategies aimed at enhancing immune responses, such as combination therapies and nanotechnology-based drug delivery systems, are actively being investigated to improve efficacy. This review also underscores the critical role of the tumor microenvironment and epithelial-mesenchymal transition (EMT) in HNSCC progression and therapeutic resistance. Novel approaches, including smart drug delivery systems utilizing nanotechnology and immune modulation, are opening new avenues for more personalized and effective treatments. Ongoing interdisciplinary research into molecular targets and advanced drug delivery techniques holds great promise for significantly improving patient outcomes in HNSCC.
Combining Radiotherapy and Immunotherapy in Head and Neck Cancer

Juliana Runnels,Julie R. Bloom,Kristin Hsieh,Daniel R. Dickstein,Yuhao Shi,Brianna M. Jones,Eric J. Lehrer,Richard L. Bakst

DOI: https://doi.org/10.3390/biomedicines11082097

IF: 4.757

2023-07-26

Biomedicines

Abstract:Head and neck squamous cell carcinoma (HNSCC) is a leading cause of morbidity and mortality globally. Despite significant advances in well-established treatment techniques, prognosis for advanced-stage HNSCC remains poor. Recent, accumulating evidence supports a role for immunotherapy in HNSCC treatment. Radiation therapy (RT), a standard treatment option for HNSCC, has immunomodulatory and immunostimulatory effects that may enhance the efficacy of immunotherapy. In several cancer types, combining RT and immunotherapy has been shown to improve tumor response rates, increase survival, and reduce toxicity compared to traditional chemotherapy and radiation therapy. This review provides a timely overview of the current knowledge on the use of RT and immunotherapy for treating HNSCC. It highlights the potential advantages of combining these therapies, such as improved tumor response rates, increased survival, and reduced toxicity. The review also discusses the challenges that need to be addressed when redefining the standard of care in HNSCC, and proposes further research to optimize treatment combinations, minimize radiation-induced toxicity, and identify suitable patient populations for treatment.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Emerging tyrosine kinase inhibitors for head and neck cancer

Zhen Long,Jennifer R Grandis,Daniel E Johnson

DOI: https://doi.org/10.1080/14728214.2022.2125954

Abstract:Introduction: Conventional regimens for head and neck squamous cell carcinoma (HNSCC) are limited in efficacy and are associated with adverse toxicities. Food and Drug Administration (FDA) approved molecular targeting agents include the HER1 (EGFR)-directed monoclonal antibody cetuximab and the immune checkpoint inhibitors nivolumab and pembrolizumab. However, clinical benefit is only seen in roughly 15-20% of HNSCC patients treated with these agents. New molecular targeting agents are needed that either act with monotherapeutic activity against HNSCC tumors or enhance the activities of current therapies, particularly immunotherapy. Small-molecule tyrosine kinase inhibitors (TKIs) represent a viable option toward this goal. Areas covered: This review provides an update on TKIs currently under investigation in HNSCC. We focus our review on data obtained and trials underway in HNSCC, including salivary gland cancers and nasopharyngeal carcinomas, but excluding thyroid cancer and esophageal cancer. Expert opinion: While some emerging TKIs have shown clinical benefit, the positive effects have, largely, been modest. The design of clinical trials of TKIs has been hampered by a lack of understanding of biomarkers that can be used to define patient populations most likely to respond. Further preclinical and translational studies to define biomarkers of TKI response will be critically important.
Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas

Hua Yao,Chenwei Yang,Ling Shen,Xinhua Gu,Changyan Chen,Xianglin Shi,Zhuo Zhang

DOI: https://doi.org/10.2174/2211552811201010026

2012-01-01

Current Angiogenesis

Abstract:Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide. Following the conventional treatment, most patients with advanced HNSCC often face a considerable risk of locoregional disease recurrence, due to the occurrence of the resistance to therapy or of metastasis. Despite continued advances in the therapeutic options, the traditional therapies conducted in HNSCC to date have largely lacked efficacy or associated with significant toxicity. Angiogenesis plays an important role in HNSCC initiation and progression. Recently, targeted angiogenesis therapy draws a broad attention, because it can specifically enhance the efficacy of chemotherapy without an increased toxicity profile. Numerous ongoing preclinical studies and clinical trials exploring anti-angiogenetic inhibitors are being tested in HNSCC. Integration targeted angiogenesis therapy with the traditional modalities of surgery, radiotherapy, and cytotoxic chemotherapy for HNSCC might be a direction in the future. This review discussed current knowledge of the targeted angiogenesis therapies, recent development of anti-angiogenesis agents, and summaries of the clinical evaluation on use of these therapies for HNSCC. Keywords: Angiogenesis, anti-angiogenesis strategy, dietary compounds, head and neck squamous cell carcinoma, targeted therapy, vascular endothelial growth factor
Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma

Aaron M. Lee,Alice N. Weaver,Phillip Acosta,Lauren Harris,Daniel W. Bowles

DOI: https://doi.org/10.3390/cancers16203488

2024-10-16

Cancers

Abstract:Head and neck squamous cell carcinoma (HNSCC) is a complex cancer requiring a multidisciplinary approach. For patients with locally or regionally advanced disease, surgery and/or radiation are the cornerstones of definitive treatment. Medical therapy plays an important adjunct role in this setting, typically consisting of a platinum-based regimen given as induction, concurrent, or adjuvant treatment. While relapsed/metastatic HNSCC has historically been a difficult-to-treat disease with poor outcomes, options have considerably improved with the incorporation of biologics and immune checkpoint inhibitors. Clinical trials are ongoing to investigate novel approaches, including new and combination immunotherapies, targeted therapies, therapeutic vaccines, antibody–drug conjugates, and cellular therapies. The results thus far have been mixed, highlighting the knowledge gaps that continue to challenge the medical oncologist treating HNSCC. Here, we present the most updated and broad review of the current treatment landscape in both locoregional and metastatic HNSCC and discuss the expansive future medical therapies under investigation.

oncology
Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma

Zheng Jiang,Xin Yang,Mailudan Ainiwaer,Fei Chen,Jun Liu

DOI: https://doi.org/10.3390/jcm12010173

IF: 3.9

2022-12-27

Journal of Clinical Medicine

Abstract:Head and neck squamous cell carcinoma (HNSCC) has long been one of the most prevalent cancers worldwide; even though treatments such as surgery, chemotherapy, radiotherapy and immunotherapy have been proven to benefit the patients and prolong their survival time, the overall five-year survival rate is still below 50%. Hence, the development of new therapies for better patient management is an urgent need. External stimuli-responsive therapies are emerging therapies with promising antitumor effects; therapies such as photodynamic (PDT) and photothermal therapies (PTT) have been tested clinically in late-stage HNSCC patients and have achieved promising outcomes, while the clinical translation of sonodynamic therapy (SDT), radiodynamic therapy (RDT), microwave dynamic/thermodynamic therapy, and magnetothermal/magnetodynamic therapy (MDT/MTT) still lag behind. In terms of preclinical studies, PDT and PTT are also the most extensively studied therapies. The designing of nanoparticles and combinatorial therapies of PDT and PTT can be referenced in designing other stimuli-responsive therapies in order to achieve better antitumor effects as well as less toxicity. In this review, we consolidate the advancements and limitations of various external stimuli-responsive therapies, as well as critically discuss the prospects of this type of therapies in HNSCC treatments.

medicine, general & internal
Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine

Linah A. Shahoumi,W. Andrew Yeudall

DOI: https://doi.org/10.1007/s13167-019-00177-y

2019-07-20

Abstract:Head and neck squamous cell carcinoma (HNSCC) develops in the mucosal lining of the upper aerodigestive tract, principally as a result of exposure to carcinogens present in tobacco products and alcohol, with oncogenic papillomaviruses also being recognized as etiological agents in a limited proportion of cases. As such, there is considerable scope for prevention of disease development and progression. However, despite multimodal approaches to treatment, tumor recurrence and metastatic disease are common problems, and clinical outcome is unsatisfactory. As our understanding of the genetics and biochemical aberrations in HNSCC has improved, so the development and use of molecularly targeted drugs to combat the disease have come to the fore. In this article, we review molecular mechanisms that alter signal transduction downstream of the epidermal growth factor receptor (EGFR) as well as those that perturb orderly cell cycle progression, such as p53 mutation, cyclin overexpression, and loss of cyclin-dependent kinase inhibitor function. We outline some of the tactics that have been employed to combat the altered biochemistry. These include blockade of the EGFR using humanized monoclonal antibodies such as cetuximab and small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib/gefitinib and subsequent generations of TKIs, restoration of p53 function using MIRA compounds, and inhibition of cyclin-dependent kinase and aurora kinase activity using drugs such as palbociclib and alisertib. Knowledge of the underlying molecular mechanisms may be utilizable in order to predict disease behavior and tailor therapeutic interventions in a more personalized approach to improve clinical response. Use of liquid biopsy, omics platforms, and salivary diagnostics hold promise in this regard.

medicine, research & experimental
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma

Andre Cassell,Jennifer R Grandis

DOI: https://doi.org/10.1517/13543781003769844

Abstract:Importance of the field: EGFR is an established therapeutic target in head and neck squamous cell carcinoma (HNSCC). The EGFR-targeting monoclonal antibody cetuximab (Erbitux, Imclone Systems, Inc., Branchburg, USA) was FDA-approved for use in HNSCC in 2006. The molecular basis for the efficacy of an antibody approach compared with inhibition of EGFR tyrosine kinase function using small-molecule inhibitors, or downregulation of protein expression via antisense strategies, remains incompletely understood. Areas covered in this review: A literature search was performed to identify studies elucidating mechanisms of action of several approaches to targeting EGFR in HNSCC (monoclonal antibodies, tyrosine kinase inhibitors, antisense approaches, and ligand-toxin conjugates). What the reader will gain: Monoclonal antibodies decrease tumor growth via receptor endocytosis and recruitment of host immune defenses. Tyrosine kinase inhibitors bind to the ATP binding pocket of the tyrosine kinase domain, inhibiting signaling. Antisense approaches decrease EGFR expression with high specificity, though drug delivery remains problematic. Ligand-toxin conjugates facilitate the entry of toxin and the ADP-ribosylation of the ribosome, thereby inhibiting translation. Take home message: Elucidation mechanisms by which these different strategies inhibit EGFR function may enhance the development of more effective treatments for HNSCC and enable prospective identification of individuals who will benefit from EGFR inhibition.
Radiotherapy and Systemic Therapies: Focus on Head and Neck Cancer

Francesca De Felice,Carlo Guglielmo Cattaneo,Pierfrancesco Franco

DOI: https://doi.org/10.3390/cancers15174232

2023-08-25

Cancers

Abstract:Head and neck squamous cell carcinoma (HNSCC) is a complex clinical entity, and its treatment strategy remains a challenge. The best practice management for individual HNSCC patients should be discussed within a multidisciplinary team. In the locally advanced disease, radiation therapy (RT) with or without concomitant cisplatin-based chemotherapy is the current standard of care for most patients treated definitively or adjuvantly after surgery. Intensity-modulated photon therapy (IMRT) is the recommended RT technique due to its ability to offer considerable treatment conformality while sparing surrounding normal critical tissues. At present, the development of novel treatment strategies, as well as alternative systemic agent combinations, is an urgent need to improve the therapeutic ratio in HNSCC patients. Despite the immune landscape suggesting a strong rationale for the use of immunotherapy agents in HNSCC, evidence-based data demonstrate that combining RT with immune checkpoint inhibitors as the primary treatment modality has not been shown to induce significant benefit on survival clinical outcomes. The objective of this article is to review the current literature on the treatment of patients with HNSCC. We initially provided a comprehensive overview of the standard of care. We then focused on the integration of systemic therapies with RT, highlighting the latest published evidence and ongoing trials which investigate different combination strategies in the definitive setting. Our hope is to summarize relevant literature in order to provide a foundation for interpreting emerging data and designing future trials to maximize care, both in disease control and patient quality of life.

oncology
White lesions of the oral cavity.

D. Messadi,J. Waibel,G. Mirowski

DOI: https://doi.org/10.1016/S0733-8635(02)00069-4

Abstract:
Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy

Hong-Xia Li,Yu-Wen Gong,Pi-Jun Yan,Yong Xu,Gang Qin,Wei-Ping Wen,Fang-Yuan Teng

DOI: https://doi.org/10.3389/fimmu.2024.1453753

IF: 7.3

2024-11-29

Frontiers in Immunology

Abstract:Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignant tumor globally. Despite advancements in treatment methods, the overall survival rate remains low due to limitations such as poor targeting and low bioavailability, which result in the limited efficacy of traditional drug therapies. Nanomedicine is considered to be a promising strategy in tumor therapy, offering the potential for maximal anti-tumor effects. Nanocarriers can overcome biological barriers, enhance drug delivery efficiency to targeted sites, and minimize damage to normal tissues. Currently, various nano-carriers for drug delivery have been developed to construct new nanomedicine. This review aims to provide an overview of the current status of HNSCC treatment and the necessity of nanomedicine in improving treatment outcomes. Moreover, it delves into the research progress of nanomedicine in HNSCC treatment, with a focus on enhancing radiation sensitivity, improving the efficacy of tumor immunotherapy, effectively delivering chemotherapy drugs, and utilizing small molecule inhibitors. Finally, this article discussed the challenges and prospects of applying nanomedicine in cancer treatment.

immunology
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

Hui-Ching Wang,Leong-Perng Chan,Shih-Feng Cho

DOI: https://doi.org/10.3389/fonc.2019.01084

IF: 4.7

2019-10-15

Frontiers in Oncology

Abstract:Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive solid tumor, with a 5-year mortality rate of ~50%. The development of immunotherapies has improved the survival of patients with HNSCC, but, the long-term prognosis of patients with recurrent or metastatic HNSCC remains poor. HNSCC is characterized by intratumoral infiltration of regulatory T cells, dysfunctional natural killer cells, an elevated Treg/CD8<sup>+</sup> T cell ratio, and increased programmed cell death ligand 1 protein on tumor cells. This leads to an immunocompromised niche in favor of the proliferation and treatment resistance of cancer cells. To achieve an improved treatment response, several potential combination strategies, such as increasing the neoantigens for antigen presentation and therapeutic agents targeting components of the tumor microenvironment, have been explored and have shown promising results in preclinical studies. In addition, large-scale bioinformatic studies have also identified possible predictive biomarkers of HNSCC. As immunotherapy has shown survival benefits in recent HNSCC clinical trials, a comprehensive investigation of immune cells and immune-related factors/cytokines and the immune profiling of tumor cells during the development of HNSCC may provide more insights into the complex immune microenvironment and thus, facilitate the development of novel immunotherapeutic agents.

oncology
Clinical update on head and neck cancer: molecular biology and ongoing challenges

Elham Alsahafi,Katheryn Begg,Ivano Amelio,Nina Raulf,Philippe Lucarelli,Thomas Sauter,Mahvash Tavassoli

DOI: https://doi.org/10.1038/s41419-019-1769-9

2019-07-15

Cell Death and Disease

Abstract:Head and neck squamous cell carcinomas (HNSCCs) are an aggressive, genetically complex and difficult to treat group of cancers. In lieu of truly effective targeted therapies, surgery and radiotherapy represent the primary treatment options for most patients. But these treatments are associated with significant morbidity and a reduction in quality of life. Resistance to both radiotherapy and the only available targeted therapy, and subsequent relapse are common. Research has therefore focussed on identifying biomarkers to stratify patients into clinically meaningful groups and to develop more effective targeted therapies. However, as we are now discovering, the poor response to therapy and aggressive nature of HNSCCs is not only affected by the complex alterations in intracellular signalling pathways but is also heavily influenced by the behaviour of the extracellular microenvironment. The HNSCC tumour landscape is an environment permissive of these tumours' aggressive nature, fostered by the actions of the immune system, the response to tumour hypoxia and the influence of the microbiome. Solving these challenges now rests on expanding our knowledge of these areas, in parallel with a greater understanding of the molecular biology of HNSCC subtypes. This update aims to build on our earlier 2014 review by bringing up to date our understanding of the molecular biology of HNSCCs and provide insights into areas of ongoing research and perspectives for the future.

cell biology
Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma

Shaokun Liu,Ru Wang,Jugao Fang

DOI: https://doi.org/10.1007/s12672-024-00870-z

2024-01-31

Discover Oncology

Abstract:The global prevalence of head and neck malignancies positions them as the sixth most common form of cancer, with the head and neck squamous cell carcinoma (HNSCC) representing the predominant histological subtype. Despite advancements in multidisciplinary approaches and molecular targeted therapies, the therapeutic outcomes for HNSCC have only marginally improved, particularly in cases of recurrent or metastatic HNSCC (R/MHNSCC). This situation underscores the critical necessity for the development of innovative therapeutic strategies. Such strategies are essential not only to enhance the efficacy of HNSCC treatment but also to minimize the incidence of associated complications, thus improving overall patient prognosis. Cancer immunotherapy represents a cutting-edge cancer treatment that leverages the immune system for targeting and destroying cancer cells. It's applied to multiple cancers, including melanoma and lung cancer, offering precision, adaptability, and the potential for long-lasting remission through immune memory. It is observed that while HNSCC patients responsive to immunotherapy often experience prolonged therapeutic benefits, only a limited subset demonstrates such responsiveness. Additionally, significant clinical challenges remain, including the development of resistance to immunotherapy. The biological characteristics, dynamic inhibitory changes, and heterogeneity of the tumor microenvironment (TME) in HNSCC play critical roles in its pathogenesis, immune evasion, and therapeutic resistance. This review aims to elucidate the functions and mechanisms of anti-tumor immune cells and extracellular components within the HNSCC TME. It also introduces several immunosuppressive agents commonly utilized in HNSCC immunotherapy, examines factors influencing the effectiveness of these treatments, and provides a comprehensive summary of immunotherapeutic strategies relevant to HNSCC.

English Else
Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature

Qichao Hong,Shun Ding,Chengliang Xing,Zhonglin Mu

DOI: https://doi.org/10.1097/md.0000000000037387

IF: 1.6

2024-03-13

Medicine

Abstract:Head and neck cancer is regarded as the seventh most common cancer in the world in the light of the Global Cancer Report 2020. With annual new incidence and death rates increasingly growing year by year, head and neck squamous cell cancer carcinoma (HNSCC) is viewed as the most common type yet of cancer. [ 1 , 2 ] The current treatment plan for HNSCC is mainly the comprehensive treatment combined with surgery, radiotherapy and chemotherapy. In recent years, there exist many different ways including traditional Chinese medicine therapy, molecular targeted therapy, immunotherapy and other treatment methods which have gradually been paid tremendous attention by people. [ 3 ] In advanced tumors, however, these treatments are often less effective. And the main causes of death in patients suffering from advanced HNSCS are concerned with local recurrence, lymphatic metastases in the neck and standard chemotherapy as well as drug resistance, which all will result in treatment failure. [ 4 ] Although patients with the later-stage HNSCC have been treated, the 5-year survival rate for them still remains quite low, at about 40% to 50%. [ 5 ] Therefore, it is a key clue to seek an effective therapeutic target or prognostic biomarker.

medicine, general & internal
Nanomedicine in HNSCC therapy-a challenge to conventional therapy

Chenyu Li,Yuan Fang,Sanchun Xu,Jingyuan Zhao,Deshi Dong,Shuai Li

DOI: https://doi.org/10.3389/fphar.2024.1434994

IF: 5.6

2024-10-15

Frontiers in Pharmacology

Abstract:Squamous cell carcinoma of the head and neck (HNSCC) is a difficult-to-treat cancer and treatment is challenging due to recurrence or metastasis. Therefore, there is an urgent need to explore more effective targeted therapies to improve the clinical outcomes and survival of HNSCC patients. The nanomedicine is emerging as a promising strategy to achieve maximal anti-tumor effect in cancer therapy. In this review, we summarize some important signaling pathways and present the current and potential roles of various nanomaterial drug-delivery formulations in HNSCC treatment, aiming to understand the pathogenesis of HNSCC and further improve the therapeutic efficacy of nanomaterial HNSCC. This article seeks to highlight the exciting potential of novel nanomaterials for targeted cancer therapy in HNSCC and thus provide motivation for further research in this field.

pharmacology & pharmacy

A pharmacological study of Cyperus rotundus.

Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review

Advances in Nonsurgical Treatment of Head and Neck Squamous Cell Carcinoma

Nanoparticle-Based Targeted Therapeutics In Head-And-Neck Cancer

Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists

New Advances in the Therapeutic Strategy of Head and Neck Squamous Cell Carcinoma: A Review of Latest Therapies and Cutting-Edge Research

Combining Radiotherapy and Immunotherapy in Head and Neck Cancer

Emerging tyrosine kinase inhibitors for head and neck cancer

Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas

Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma

Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma

Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine

Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma

Radiotherapy and Systemic Therapies: Focus on Head and Neck Cancer

White lesions of the oral cavity.

Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy

Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

Clinical update on head and neck cancer: molecular biology and ongoing challenges

Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma

Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature

Nanomedicine in HNSCC therapy-a challenge to conventional therapy